A homotropic two-state model and auto-antagonism

BMC Pharmacology

Volumn 4, Issue , 2004, Pages

  Bindslev, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CYCLIC AMP; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; LIGAND; METHACHOLINE; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; PROLACTIN; PROLACTIN RECEPTOR; PROSTACYCLIN; PROSTAGLANDIN E2; TRACER;

ALLOSTERISM; ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BINDING SITE; CHEMICAL MODEL; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DESENSITIZATION; DIMERIZATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INHIBITION; EXOCRINE SECRETION; ISOMERIZATION; LIGAND BINDING; NONHUMAN; PROTEIN DETERMINATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRACHEA MUCOSA; BIOLOGICAL MODEL;

ALLOSTERIC REGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; LIGANDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL;

EID: 12944265070     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-4-11     Document Type: Article

References (67)

1. Changeux JP: Allosteric proteins: from regulatory enzymes to receptors - personal recollections. Bioessays 1993, 15: 25-634.
2. Maksay G, Thompson SA, Wafford KA: Allosteric modulators affect the efficacy of partial agonists for recombinant GABA(A) receptors. Br J Pharmacol 2000, 129:1794-1800.
3. Leppik RA, Mynett A, Lazareno S, Birdsall NJ: Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor. Mol Pharmacol 2000, 57: 36-445.
4. Helmstaedt K, Krappmann S, Braus GH: Allosteric regulation of catalytic activity: Escherichia coli aspartate transcarbamoylase versus yeast chorismate mutase. Microbiol Mol Biol Rev 2001, 65:404-421.
5. Christopoulos A, Kenakin T: G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002, 54: 23-374.
6. Gasparini F, Kuhn R, Pin JP: Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2002, 2: 3-49.
7. Monod J, Wyman J, Changeux J-P: On the nature of allosteric transitions: A plausible model. J Mol Biol 1965, 12:88-118.
8. Ricard J, Cornish-Bowden A: Co-operative and allosteric enzymes: 20 years on. Eur J Biochem 1987, 166:255-272.
9. Gamage NU, Duggleby RG, Barnett AC, Tresillian M, Latham CF, Liyou NE, McManus ME, Martin JL: Structure of a human carcinogen-converting enzyme, SULT1A1. Structural and kinetic implications of substrate inhibition. J Biol Chem 2003, 278: 655-7662.
10. He YA, Roussel F, Halpert JR: Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 2003, 409:92-101.
11. Arias HR: Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor. J Neurosci Res 1996, 44: 7-105.
12. Lombardi G, Dianzani C, Miglio G, Canonico PL, Fantozzi R: Characterization of ionotropic glutamate receptors in human lymphocytes. Br J Pharmacol 2001, 133:936-944.
13. Borst P, Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002, 71:537-592.
14. Incerpi S, D'Arezzo S, Marino M, Musanti R, Pallottini V, Pascolini A, Trentalance A: Short-term activation by low 17beta-estradiol concentrations of the Na+/H+ exchanger in rat aortic smooth muscle cells: physiopathological implications. Endocrinology 2003, 144:4315-4324.
15. Henry ER, Bettati S, Hofrichter J, Eaton WA: A tertiary two-state allosteric model for hemoglobin. Biophys Chem 2002, 98:149-164.
16. Leiser J, Conn PM, Blum JJ: Interpretation of dose-response curves for luteinizing hormone release by gonadotropinreleasing hormone, related peptides, and leukotriene C4 according to a hormone/receptor/effector model. Proc Natl Acad Sci U S A 1986, 83:5963-7.
17. Schlessinger J: Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 1988, 13:443-447.
18. Winding B, Bindslev N: Desensitization and reactivation of ACh-regulated exocrine secretion in hen tracheal epithelium. Am J Physiol 1993, 264:C342-C351.
19. Chidiac P, Nouet S, Bouvier M: Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Mol Pharmacol 1996, 50:662-669.
20. Bronnikov GE, Zhang SJ, Cannon B, Nedergaard J: A dual component analysis explains the distinctive kinetics of cAMP accumulation in brown adipocytes. J Biol Chem 1999, 274:37770-37780.
21. Cuthbert AW: Benzoquinolines and chloride secretion in murine colonic epithelium. Br J Pharmacol 2003, 138: 528-1534.
22. Hornigold DC, Mistry R, Raymond PD, Blank JL, Challiss RA: Evidence for cross-talk between M2 and M3 muscarinic acetylcholine receptors in the regulation of second messenger and extracellular signal-regulated kinase signalling pathways in Chinese hamster ovary cells. Br J Pharmacol 2003, 138:1340-1350.
23. Griffin MT, Hsu JC, Shehnaz D, Ehlert FJ: Comparison of the pharmacological antagonism of M2 and M3 muscarinic receptors expressed in isolation and in combination. Biochem Pharmacol 2003, 65:1227-1241.
24. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA: Rational design of potent antagonists to the human growth hormone receptor. Science 1992, 256:1677-80.
25. Talmadge JE: Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 1998, 33:241-252.
26. Kühl PW: Excess-substrate inhibition in enzymology and highdose inhibition in pharmacology: a reinterpretation [corrected]. Biochem J 1994, 298:171-180.
27. Kaiser PM: Substrate inhibition as a problem of non-linear steady state kinetics with monomeric enzymes. J Mol Catal 1980, 8:431-442.
28. De Meyts P, Urso B, Christoffersen CT, Shymko RM: Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. Ann N Y Acad Sci 1995, 766:388-401.
29. Metzger H: Molecular versatility of antibodies. Immunol Rev 2002, 185:186-205.
30. Rios CD, Jordan BA, Gomes I, Devi LA: G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 2001, 92:71-87.
31. Proška J, Tuček S: Competition between positive and negative allosteric effectors on muscarinic receptors. Mol Pharmacol 1995, 48:696-702.
32. Ellis J: Allosteric binding sites on muscarinic receptors. Drug Dev Res 1997, 40:193-204.
33. Zelcer N, Huisman MT, Reid G, Wielinga PR, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, Borst P: Evidence for two interacting ligand-binding sites in human MRP2 (ABCC2). J Biol Chem 2003, 278:23538-23544.
34. Hall DA: Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 2000, 58: 412-1423.
35. Weiss JM, Morgan PH, Lutz MW, Kenakin TP: The Cubic Ternary Complex Receptor-Occupancy Model I. Model Description. J Theor Biol 1996, 178:151-167.
36. Weiss JM, Morgan PH, Lutz MW, Kenakin TP: The Cubic Ternary Complex Receptor-Occupancy Model II. Understanding Apparent Affinity. J Theor Biol 1996, 178:169-182.
37. Weiss JM, Morgan PH, Lutz MW, Kenakin TP: The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J Theor Biol 1996, 181:381-397.
38. Kinet S, Bernichtein S, Kelly PA, Martial JA, Goffin V: Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites. J Biol Chem 1999, 274:26033-26043.
39. Accomazzo MR, Cattaneo S, Nicosia S, Rovati GE: Bell-shaped curves for prostaglandin-induced modulation of adenylate cyclase: two mutually opposing effects. Eur J Pharmacol 2002, 454:107-114.
40. Wreggett KA, Wells JW: Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J Biol Chem 1995, 270:22488-22499.
41. Avlani V, May LT, Sexton PM, Christopoulos A: Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2004, 308:1062-72.
42. Zeng F, Wess J: Molecular aspects of muscarinic receptor dimerization. Neuropsycho-pharmacology 2000, 23:S19-31.
43. Migeon JC, Nathanson NM: Differential regulation of cAMP-mediated gene transcription by m1 and m4 muscarinic acetylcholine receptors. Preferential coupling of m4 receptors to Gi alpha-2. J Biol Chem 1994, 269:9767-9773.
44. Goffin V, Binart N, Touraine P, Kelly PA: Prolactin: the new biology of an old hormone. Annu Rev Physiol 2002, 64: 7-67.
45. Colquhoun D: Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 1998, 125: 24-947.
46. Polc P, Bonetti EP, Schaffner R, Haefely W: A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone. Naunyn - Schmiedebergs Arch Pharmacol 1982, 321:260-264.
47. Rees S, Morrow D, Kenakin T: GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 2002, 8:261-268.
48. Haldane JBS: Enzymes London: Longmans, Green & Co; 1930:84-85.
49. Murray DRP: The inhibition of esterases by excess substrate. Biochem J 1930, 24:1890-96.
50. Laidler KJ, Hoare JP: The molecular kinetics of the urea-urease system. I. The kinetic laws. J Am Chem Soc 1949, 71:2699-2702.
51. Ariëns EJ, Simonis AM, De Groot WM: Affinity and intrinsic-activity in the theory of competitive- and non-competitive inhibition and an analysis of some forms of dualism in action. Arch int pharmacodyn 1955, 100:298-322.
52. Sakolsky DJ, Ashby B: Patterns of cyclic AMP formation by coexpressed D1 and D2L dopamine receptors in HEK 293 cells. Receptors Channels 2001, 7:479-489.
53. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 2002, 30:1512-1522.
54. Katz B, Thesleff S: A study of the 'desensitization' produced by acetylcholine at the motor end-plate. J Physiol 1957, 138:63-80.
55. Leff P: The two-state model of receptor activation. Trends Pharmacol Sci 1995, 16:89-97.
56. Watanabe S, Tonomura Y, Shiokawa H: Mechanism of muscular contraction. II. Kinetic studies on muscle ATP-ase. J Biochem 1953, 40:387-402.
57. Blum JJ: The enzymatic interaction between myosin and nucleotides. Arch Biochem Biophys 1955, 55:486-511.
58. Botts J, Drain GF: An illustration of a kinetic analysis: The myosin B-ATP-EDTA system. In Conference on the chemistry of muscular contraction 1957 Edited by: The committee of muscle chemistry of Japan. Tokyo: Igaku Shoin; 1958:33-41.
59. Koshland DE Jr, Nemethy G, Filmer D: Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 1966, 5:365-385.
60. De Haën C: The non-stoichiometric floating receptor model for hormone sensitive adenylyl cyclase. J Theor Biol 1976, 58:383-400.
61. Paton WDM: A theory of drug action based on the rate of drug-receptor combination. Proc Roy Soc Lond 1961, 154: 1-69.
62. 125I-glucagon. J Biol Chem 1971, 246:1872-1876.
63. Sternweis PC, Northup JK, Smigel MD, Gilman AG: The regulatory component of adenylate cyclase. Purification and properties. J Biol Chem 1981, 256:11517-11526.
64. De Lean A, Stadel JM, Lefkowitz RJ: A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 1980, 255:7108-7117.
65. Costa T, Herz A: Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci 1989, 86:7321-7325.
66. Samama P, Cotecchia S, Costa T, Lefkowitz RJ: A mutationinduced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 1993, 268 4625-4636.
67. Kenakin T, Morgan P, Lutz M, Weiss J: The evolution of drugreceptor models: The cubic ternary complex model for G protein-coupled receptors. In The pharmacology of functional, biochemical, and recombinant receptor systems Edited by: Kenakin T, Angus JA. Berlin: Springer Verlag; 2000:147-165.